AI assistant
Sending…
Summit Therapeutics Inc. — Director's Dealing 2023
Mar 8, 2023
30436_dirs_2023-03-08_454cf2cb-3bee-46ac-8580-2b46a6148415.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2023-03-06
Reporting Person: DUGGAN ROBERT W (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-03-06 | Common Stock | P | 376489880 | $1.05 | Acquired | 552354161 | Direct |
Footnotes
F1: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering.
More from Summit Therapeutics Inc.
Capital/Financing Update
2026
Jun 3
Regulatory Filings
2026
Jun 1
Interim / Quarterly Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 17
Annual Report
2026
Feb 23
Earnings Release
2026
Feb 23
Regulatory Filings
2026
Jan 29
Director's Dealing
2026
Jan 12
Regulatory Filings
2026
Jan 12
Director's Dealing
2026
Jan 7